First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM).

被引：0
|
作者：
Plummer, R.
Lorigan, P.
Evans, J.
Steven, N.
Middleton, M.
Wilson, R.
Snow, K.
Dewji, R.
Calvert, H.
机构：
[1] No Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England
[2] Chrisite Hosp, Manchester, Lancs, England
[3] Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland
[4] Inst Canc Studies, Birmingham, W Midlands, England
[5] Canc Res UK, Oxford, England
[6] Queens Univ Belfast, Belfast, Antrim, North Ireland
[7] Pfizer GRD, Sandwich, Kent, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：456S / 456S
页数：1
相关论文
共 50 条
  • [31] BEVATEM: Phase II study of bevacizumab (B) in combination with temozolomide (T) in patients (pts) with first-line metastatic uveal melanoma (MUM): Final results
    Piperno-Neumann, Sophie
    Servois, Vincent
    Bidard, Francois-Clement
    Mariani, Pascale
    Plancher, Corine
    Diallo, Alhassane
    Vago-Ady, Nora
    Desjardins, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] Phase II trial of combination thalidomide (thal) plus temozolomide (TMZ [TT]), in patients with metastatic malignant melanoma (MMM): Southwest Oncology Group S0508
    Clark, J.
    Moon, J.
    Hutchins, L. F.
    Sosman, J. A.
    Kast, W. M.
    Da Silva, D.
    Liu, P. Y.
    Thompson, J. A.
    Sondak, V. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer
    Shivaani Kummar
    James L. Wade
    Amit M. Oza
    Daniel Sullivan
    Alice P. Chen
    David R. Gandara
    Jiuping Ji
    Robert J. Kinders
    Lihua Wang
    Deborah Allen
    Geraldine O’Sullivan Coyne
    Seth M. Steinberg
    James H. Doroshow
    Investigational New Drugs, 2016, 34 : 355 - 363
  • [34] Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer
    Kummar, Shivaani
    Wade, James L.
    Oza, Amit M.
    Sullivan, Daniel
    Chen, Alice P.
    Gandara, David R.
    Ji, Jiuping
    Kinders, Robert J.
    Wang, Lihua
    Allen, Deborah
    Coyne, Geraldine O'Sullivan
    Steinberg, Seth M.
    Doroshow, James H.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 355 - 363
  • [35] Phase 0 pharmacodynamic study of poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with refractory solid tumors and lymphomas: Immunohistochemistry results
    Yang, S. X.
    Kummar, S.
    Rubinstein, L.
    Gutierrez, M.
    Murgo, A. J.
    Parchment, R. E.
    Nguyen, D.
    Chen, A. P.
    Tomaszewski, J. E.
    Doroshow, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] A phase 1 study of veliparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (SCLC) patients: An Eastern Cooperative Oncology Group study (E2511).
    Owonikoko, Taofeek Kunle
    Dahlberg, Suzanne Eleanor
    Khan, Saad A.
    Gerber, David E.
    Dowell, Jonathan
    Moss, Rebecca Anne
    Belani, Chandra Prakash
    Hann, Christine L.
    Aggarwal, Charu
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial.
    Cohen, Jared
    Ley, Jessica C.
    Liu, Jingxia
    Haselhorst, Emma
    Oppelt, Peter John
    Adkins, Douglas
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?
    Cetin, Bulent
    Wabl, Chiara A.
    Gumusay, Ozge
    FUTURE ONCOLOGY, 2022, 18 (39) : 4235 - 4238
  • [39] First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors.
    Samnotra, Vivek
    Shtessel, Veronica Moroz Luda
    Kuchimanchi, Mita
    Hanafin, Patrick
    Pannirselvam, Malar
    Bhaskar, Aishwarya
    Liu, Andrew
    Yuzugullu, Haluk
    Barve, Minal A.
    Sommerhalder, David
    Yap, Timothy A.
    Sanicola-Nadel, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study
    Fong, P. C.
    Boss, D. S.
    Carden, C. P.
    Roelvink, M.
    De Greve, J.
    Gourley, C. M.
    Carmichael, J.
    De Bono, J. S.
    Schellens, J. H.
    Kaye, S. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345